Remove section science
article thumbnail

Weekly Roundup: June 16-22, 2023

Harvard Corporate Governance

Key Components and Trends of CVRs in Life Sciences Public M&A Deals Posted by Sally Wagner Partin, Sharon Flanagan, and Hannah M. Groner, Katherine L. Romain, Michael P.

Alpha 231
article thumbnail

EXCLUSIVE: Global Psychedelics Company Silo Wellness Acquires Dyscovry Science, Including Access To Its Gov Collaborations

Benzinga

OTCQB: SILFF ) (CSE: SILO) (FSE: 3K7A) is acquiring Dyscovry Science Ltd. , According to information procured exclusively by Benzinga ahead of an official announcement , global psychedelics company Silo Wellness Inc. of National Policy 46-201- Escrow for Initial Public Offerings. Full story available on Benzinga.com.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Why did life sciences outperform the market? More than half of all life sciences M&A activity in 2023 was for private and small-cap biopharma sellers.

article thumbnail

Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors

Benzinga

Before his career in High-Tech, he had a 13-year career in medical science. Rene Sindlev, Chair of the Board of Renovaro Biosciences, said, "Avram's unique background in medical science and technology and, in particular, his experience dealing with the opportunities fueled by rapid technological changes will help guide our business.

article thumbnail

Sosei Heptares - Investor and Press Conference on Today's Announcement Regarding the Acquisition and License Transaction with Idorsia

Benzinga

Presentation slides will be made available through the investor section of the Company's Home Page here. ENDS - About Sosei Heptares Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become.

40
article thumbnail

22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform

Benzinga

Complete Hemp/Cannabis Solution from Receptor Science and Plant Genetics to Final Ingredients and CDMO. Consistent, Reliable, High-Quality Cannabinoids and Cannabinoid Infused Products for Consumers. Acquisition Immediately Accretive; Will Double 22nd Century Revenue. BUFFALO, N.Y., May 18, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc.

article thumbnail

Globex Acquires Quebec Dolomite Deposit

Benzinga

Research Department, Mineral Science. Section, Project No. Previous work by QIT Iron and Titanium in 1980-1981 consisted of 56 drill holes which outlined a historical non-NI 43-101 compliant resource of +23,405,000 tonnes grading 20.5% MgO, 30.5% CaO and 0.92% SiO 2 (QIT-Fer et Titane inc., Cossette, December 11, 1981). Marleau, D.Sc.,